Authors:

Natashya Parameswari, Sriwidodo ., Mr

Abstract:

“Tuberculosis (TB) is a respiratory tract infection that remains a global health problem to this day. There were more than 10, 6 million TB cases with approximately 1,5 million deaths in 2021. The oral therapy regimen consisting of isoniazid (INH), ethambutol (EMB), pyrazinamide (PZA) dan rifampicin (RIF), despite having a successful treatment rate up to 95% still faces limitation contributing to low treatment compliance and the development of drug-resistance Mtb strains. Strategy to overcome these limitations is to deliver drugs by inhalation as aerosols to the lung, the primary site of Mtb infection. Liposome-based nanocarriers have been proven effective in improving drug bioavailability and reducing toxicity. Therefore, this article review aims to explore the potential nanocarriers in pulmonary drug delivery systems”

Keywords

Keyword Not Available

Downloads:

Download data is not yet available.

References

References Not Available

PDF:

https://jurnal.harianregional.com/jfu/full-103245

Published

2024-01-31

How To Cite

PARAMESWARI, Natashya; ., Sriwidodo. Potential of Liposomes as Nanocarriers for Antituberculosis Inhalation Formulations.Jurnal Farmasi Udayana, [S.l.], p. 125-131, jan. 2024. ISSN 2622-4607. Available at: https://jurnal.harianregional.com/jfu/id-103245. Date accessed: 28 Aug. 2025. doi:https://doi.org/10.24843/JFU.2023.v12.i02.p08.

Citation Format

ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

Issue

Vol. 12, No. 2, tahun 2023

Section

Articles

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License